1497 / 1835
13-034 Cohort 3 Study Design, N=29
Brentuximab (1.2 mg/m
2
)+ AVD x 2 cycles
PET-CT-2
PET-CT-4
Biopsy
Bx-
Bx+
30 Gy
CVRT
Off study
Eligiblity:
•
Histologically confirmed cHL
•
Stage I or II
•
Bulky mediastinal mass (≥7cm in
MTD or MCD)
Brentuximab (1.2 mg/m
2
)+ AVD x 2 cycles